
==== Front
BMC CancerBMC CancerBMC Cancer1471-2407BioMed Central London 240310.1186/s12885-016-2403-1ErratumErratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study Bridgewater John j.bridgewater@ucl.ac.uk Lopes Andre Beare Sandra Duggan Marian Lee Dymphna Ricamara Maravic McEntee Delyth Sukumaran Ajithkumar Wasan Harpreet Valle Juan W.  UCL Cancer Institute, 72 Huntley St, London, WC1E 6DD UK  Cancer Research UK and UCL Clinical Trials Centre, London, UK  The Christie NHS Foundation Trust, Manchester, UK  Imperial College Healthcare, London, UK 21 6 2016 21 6 2016 2016 16 36915 6 2016 15 6 2016 © The Author(s). 2016
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.issue-copyright-statement© The Author(s) 2016
==== Body
Erratum
After publication of the original article [1], the authors noticed an error in the Acknowledgements section. The Acknowledgement contains missing information. The correct version of the Acknowledgements section is included below:

The online version of the original article can be found under doi:10.1186/s12885-016-2174-8.

Acknowledgements
The research was funded in part by AstraZeneca and carried out at, and supported by, the National Institute for Health Research (NIHR UCLH Clinical Research Facility and the Cancer Research UK Experimental Cancer Medicine Centre (ECMC). Central coordination of the study was supported by Cancer Research UK (Grant reference C1813/A12155) and AstraZeneca. Conduct of the trial at hospital sites was supported through the National Institute of Health Research Clinical Research Network and AstraZeneca. We also acknowledge the support of the AMMF (www.ammf.org.uk/) and the IBTCC (International Biliary Tract Cancer Collaboration). JB is partly funded by the UCLH/UCL NIHR Biomedical Research Centre.
==== Refs
References
1. Bridgewater J  Lopes A  Beare S  Duggan M  Lee D  Ricamara M    A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study BMC Cancer 2016 16 153 10.1186/s12885-016-2174-8 26912134
